Relationship between number of bacteria and their probiotic effects

Microbial Ecology in Health and Disease

Volumn 20, Issue 4, 2008, Pages 180-183

  Minelli, Elisa Bertazzoni ^a   Benini, Anna ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Acute infectious diarrhoea; Efficacy; Immunological disease; Probiotics

Indexed keywords

PROBIOTIC AGENT; VSL3;

ACUTE DIARRHEA; ALLERGIC DISEASE; ARTICLE; BACTERIAL NUMBER; COLITIS; COLON; COLONY FORMING UNIT; DIARRHEA; DRUG EFFICACY; GASTROINTESTINAL INFECTION; HEALTH; HUMAN; ILEITIS; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTIOUS DIARRHEA; INFLAMMATORY DISEASE; MICROBIOLOGICAL PARAMETERS; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; TREATMENT DURATION;

EID: 57649112545     PISSN: 0891060X     EISSN: 16512235     Source Type: Journal    
DOI: 10.1080/08910600802408095     Document Type: Article

References (20)

1. Christensen HR, Larsen CN, Kaestel P, Rosholm LB, Sternberg C, Michaelsen KF, et al. Immunomodulating potential of supplementation with probiotics: a dose-response study in healthy young adults. FEMS Immunol Med Microbiol. 2006;47:380-90.
2. Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol. 2003;17:725-40.
3. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004;CD003048.
4. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374-82.
5. Vesa T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther. 2000;14:823-8.
6. Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci. 1999;82:863-9.
7. Sanders ME. Probiotics: considerations for human health. Nutr Rev. 2003;61:91-9.
8. Oozeer R, Leplingard A, Mater DD, Mogenet A, Michelin R, Seksek I, et al. Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl Environ Microbiol. 2006;72:5615-7.
9. Elmer GW, Corthier G. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol. 1991;37:315-7.
10. Girard P, Pansart Y, Lorette I, Gillardin JM. Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor oil-induced diarrhea in rats. Dig Dis Sci. 2003;48:770-4.
11. Sanders ME, Veld JH. Bringing a probiotic-containing functional food to the market: microbiological, product, regulatory and labelling issues. Antonie van Leeuwenhoek. 1999;76:293-315.
12. Gill HS, Rutherfurd KJ. Viability and dose-response studies on the effects of the immunoenhancing lactic acid bacterium Lactobacillus rhamnosus in mice. Br J Nutr. 2001;86:285-9.
13. Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, et al. Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol. 2006;12:5978-86.
14. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol. 2003;111:389-95.
15. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005;90:892-7.
16. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-33.
17. Castagliuolo I, Galeazzi F, Ferrari S, Elli M, Brun P, Cavaggioni A, et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Microbiol. 2005;43:197-204.
18. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol. 2005;174:3237-46.
19. Kühbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833-41.
20. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108-14.